WO2016019140A1 - Methods, compositions, and kits for analysis of structurally diverse complex lipids - Google Patents
Methods, compositions, and kits for analysis of structurally diverse complex lipids Download PDFInfo
- Publication number
- WO2016019140A1 WO2016019140A1 PCT/US2015/042904 US2015042904W WO2016019140A1 WO 2016019140 A1 WO2016019140 A1 WO 2016019140A1 US 2015042904 W US2015042904 W US 2015042904W WO 2016019140 A1 WO2016019140 A1 WO 2016019140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- sample
- fatty acids
- mixture
- present
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 750
- 239000000203 mixture Substances 0.000 title claims abstract description 740
- 238000000034 method Methods 0.000 title claims abstract description 176
- 238000004458 analytical method Methods 0.000 title claims description 22
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 564
- 229930195729 fatty acid Natural products 0.000 claims description 564
- 239000000194 fatty acid Substances 0.000 claims description 564
- 150000004665 fatty acids Chemical class 0.000 claims description 563
- 239000000523 sample Substances 0.000 claims description 325
- 241000894007 species Species 0.000 claims description 134
- -1 6- hydroxyceramide Chemical compound 0.000 claims description 93
- 239000012472 biological sample Substances 0.000 claims description 88
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 81
- 229910052805 deuterium Inorganic materials 0.000 claims description 81
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 70
- 125000002252 acyl group Chemical group 0.000 claims description 64
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 59
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 54
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 51
- 150000001982 diacylglycerols Chemical class 0.000 claims description 47
- YZXBAPSDXZZRGB-DOFZRALJSA-M Arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC([O-])=O YZXBAPSDXZZRGB-DOFZRALJSA-M 0.000 claims description 46
- 150000003904 phospholipids Chemical class 0.000 claims description 39
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 34
- 210000002966 serum Anatomy 0.000 claims description 32
- 150000003626 triacylglycerols Chemical class 0.000 claims description 32
- 210000002381 plasma Anatomy 0.000 claims description 30
- 235000021588 free fatty acids Nutrition 0.000 claims description 29
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 29
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 claims description 24
- 229940049964 oleate Drugs 0.000 claims description 23
- 229940106189 ceramide Drugs 0.000 claims description 22
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 22
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 22
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 21
- 238000005917 acylation reaction Methods 0.000 claims description 21
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 21
- 230000000155 isotopic effect Effects 0.000 claims description 21
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 21
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 21
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 20
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 20
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 20
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 20
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 20
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 20
- 210000002700 urine Anatomy 0.000 claims description 20
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims description 19
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 19
- CWRILEGKIAOYKP-SSDOTTSWSA-M [(2r)-3-acetyloxy-2-hydroxypropyl] 2-aminoethyl phosphate Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCCN CWRILEGKIAOYKP-SSDOTTSWSA-M 0.000 claims description 19
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 claims description 19
- 229930183167 cerebroside Natural products 0.000 claims description 19
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims description 19
- 150000002270 gangliosides Chemical class 0.000 claims description 19
- 150000002305 glucosylceramides Chemical class 0.000 claims description 19
- 229930000756 phytoceramide Natural products 0.000 claims description 19
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 18
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
- 150000003727 wax diesters Chemical class 0.000 claims description 17
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims description 16
- 125000005313 fatty acid group Chemical group 0.000 claims description 16
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims description 16
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims description 15
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 15
- 238000004587 chromatography analysis Methods 0.000 claims description 15
- UOXRPRZMAROFPH-IESLQMLBSA-N lysophosphatidylinositol Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC1[C@H](O)[C@@H](O)C(O)[C@@H](O)[C@H]1O UOXRPRZMAROFPH-IESLQMLBSA-N 0.000 claims description 15
- 238000004949 mass spectrometry Methods 0.000 claims description 15
- 102000004895 Lipoproteins Human genes 0.000 claims description 14
- 108090001030 Lipoproteins Proteins 0.000 claims description 14
- 239000004164 Wax ester Substances 0.000 claims description 14
- 235000019386 wax ester Nutrition 0.000 claims description 14
- 230000001413 cellular effect Effects 0.000 claims description 13
- 210000004880 lymph fluid Anatomy 0.000 claims description 13
- 210000003296 saliva Anatomy 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 238000004817 gas chromatography Methods 0.000 claims description 12
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 12
- 238000004809 thin layer chromatography Methods 0.000 claims description 11
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 10
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 10
- 239000012805 animal sample Substances 0.000 claims description 10
- 125000000403 lignoceroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 238000005251 capillar electrophoresis Methods 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 229940000640 docosahexaenoate Drugs 0.000 claims description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 7
- 229940066279 eicosapentaenoate Drugs 0.000 claims description 6
- 238000004255 ion exchange chromatography Methods 0.000 claims description 5
- 238000004007 reversed phase HPLC Methods 0.000 claims description 5
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 4
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
- 239000013068 control sample Substances 0.000 claims description 3
- 125000003473 lipid group Chemical group 0.000 claims 98
- 241001465754 Metazoa Species 0.000 claims 1
- 238000011002 quantification Methods 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 7
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 18
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 241000124008 Mammalia Species 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 230000007935 neutral effect Effects 0.000 description 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241001432959 Chernes Species 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 4
- 101100321670 Fagopyrum esculentum FA18 gene Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 125000004431 deuterium atom Chemical group 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 125000003374 diacylglycerol group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229940049918 linoleate Drugs 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007430 reference method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 101100223822 Dictyostelium discoideum zfaA gene Proteins 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001783 ceramides Chemical class 0.000 description 2
- 150000001840 cholesterol esters Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 239000010422 internal standard material Substances 0.000 description 2
- 238000010813 internal standard method Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 150000003408 sphingolipids Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003203 triacylglycerol group Chemical group 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MWXAIAMSOXOQJK-JIXVGTEKSA-N 1-hexadecanoyl-2-(4Z,7Z,10Z,13Z,16Z-docosapentaenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC MWXAIAMSOXOQJK-JIXVGTEKSA-N 0.000 description 1
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 1
- WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 1
- LUZYTSCABOWJAC-HLJNGVMWSA-N 6-hydroxysphing-4E-enine Chemical compound CCCCCCCCCCCCC(O)\C=C\[C@@H](O)[C@@H](N)CO LUZYTSCABOWJAC-HLJNGVMWSA-N 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 1
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 description 1
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 108010030678 Phosphatidylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 102000005920 Phosphatidylethanolamine N-methyltransferase Human genes 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- 208000032001 Tyrosinemia type 1 Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940114078 arachidonate Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- RORSDNHKRISNBL-UHFFFAOYSA-N azanium dichloromethane acetate Chemical compound C(Cl)Cl.C(C)(=O)[O-].[NH4+] RORSDNHKRISNBL-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000000769 gas chromatography-flame ionisation detection Methods 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 238000002552 multiple reaction monitoring Methods 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-GTFORLLLSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCC[14C](O)=O QIQXTHQIDYTFRH-GTFORLLLSA-N 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- YWAKXRMUMFPDSH-UHFFFAOYSA-N pentene Chemical compound CCCC=C YWAKXRMUMFPDSH-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- 125000002657 sphingoid group Chemical group 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005672 tetraenes Chemical class 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 201000007972 tyrosinemia type I Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
- G01N2496/80—Multi-analyte reference solutions containing cholesterol, glucose and the like
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
- Y10T436/104165—Lipid, cholesterol, or triglyceride standard or control
Definitions
- the presently disclosed subject matter relates to methods, compositions, and kits for synthesizing and using mixtures of complex lipids as internal standards for analysis of biological samples and other samples containing mixtures of complex lipids.
- Using an internal standard to calibrate the concentration of a target compound in a sample is a well- accepted method of quantification.
- a compound is added that is not present in the sample to be tested that satisfies two criteria: (1) that the internal standard act similarly to the target compound at all stages of sample preparation (e.g. extraction,
- Lipids in biological samples are problematic targets for quantification by internal standard because they have a diverse array of chemical properties, even within a given lipid class.
- the lipids also have combinatorial complexity, for example, several of many potential fatty acids are acylated onto one of a dozen or so backbones.
- a small number of internal standards cannot meet the first of the above two criteria.
- analysts use few internal standard compounds, and most often choose only a single compound to represent a broad class of lipid (e.g., phospholipids, neutral lipids) to use as an internal standard.
- lipid internal standards are constructed from a single odd-chain or short-chain fatty acid (e.g. PC12:0/12:0 or TAG17:0/17:0/17:0). Most mixtures of internal standards use a single internal standard per broad lipid class.
- current approaches for developing internal standards are limited because: 1) short chain fatty acids or completely saturated fatty acid internal standards do not act like the target compounds in the assay and 2) it is difficult to represent the combinatorial complexity of lipids using simple internal standard strategies.
- lipid internal standards are classes of lipids with a diverse array of fatty acids attached to them.
- Methods of synthesizing and using compositions and kits that include mixtures of lipid molecules as internal standards with a sufficiently diverse composition to effectively represent the fatty acids of the complex lipid class(es) in samples of interest are provided herein .
- the internal standards are synthesized to contain the characteristics described herein.
- the synthesized internal standards may then be packaged in a kit and used for lipid analysis.
- the lipid internal standards described herein may be used in any application including, for example, mass spectrometry.
- a method for synthesizing one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, the method comprising: attaching an isotopically-labeled fatty acid at a first position on a lipid backbone through an acylation reaction for a lipid class having at least two acyl groups; and attaching a mixture of at least two different fatty acids to the lipid backbone at a separate position through an acylation reaction, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecular species present in the corresponding lipid class in the sample of interest.
- a method for synthesizing one or more mixture of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, the method comprising: attaching a mixture of at least two different fatty acids to an isotopically-labeled lipid backbone at a single position through an acylation reaction for a lipid class having at least one acyl group, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecular species present in the corresponding lipid class in the sample of interest.
- a composition for use as an internal standard comprising one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising: a lipid backbone having an isotopically-labeled fatty acid at a first position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least two acyl groups; and a mixture of at least two different fatty acids present at a separate position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecular species present in the corresponding lipid class in the sample of interest.
- a composition for use as an internal standard comprising one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising: a lipid backbone having one or more isotopic labels, wherein the lipid backbone is for a lipid class having at least one acyl group; and a mixture of at least two different fatty acids present at a single position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acids in the lipid molecular species present in the corresponding lipid class in the sample of interest.
- a kit comprising: i) one or more mixtures of lipid molecules for use as an internal standard, wherein each mixture of lipid molecules is representative of the composition of lipid molecular species present in each of one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising: a lipid backbone having an isotopically-labeled fatty acid at a first position on the lipid backbone and a mixture of at least two different fatty acids present at a separate position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least two acyl groups, or a lipid backbone having one or more isotopic labels and a mixture of at least two different fatty acids present at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample
- a method for one of detecting and quantifying lipid molecules present in a sample of interest comprising: adding to a sample of interest a known amount of a composition having one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in the sample of interest, wherein each mixture of lipid molecules comprises i) a lipid backbone having an isotopically-labeled fatty acid at a first position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least two acyl groups; and ii) a mixture of at least two different fatty acids present at a separate position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecular species present
- a method for one of detecting and quantifying lipid molecules present in a sample of interest comprising: adding to a sample of interest a known amount of a composition having one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in the sample of interest, wherein each mixture of lipid molecules comprises i) a lipid backbone having one or more isotopic labels, wherein the lipid backbone is for a lipid class having at least one acyl group; and ii) a mixture of at least two different fatty acids present at a single position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acids in the lipid molecular species present in the
- a method for synthesizing one or more mixtures of lipid molecules for use as an internal standard representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, the method comprising one or more of: attaching a mixture of at least two different isotopically-labeled fatty acids to a lipid backbone at a single position through an acylation reaction for a lipid class having at least one acyl group; attaching a mixture of at least two different fatty acids to an isotopically-labeled lipid backbone at a single position through an acylation reaction for a lipid class having at least one acyl group; or attaching a single isotopically-labeled fatty acid to a lipid backbone at a first position through an acylation reaction for a lipid class having at least two fatty acids and attaching a mixture of at least two different fatty acids to a separate position on the lipid backbone through
- a composition for use as an internal standard comprising one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising one or more of: a lipid backbone having a mixture of at least two different isotopically-labeled fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; an isotopically-labeled lipid backbone having a mixture of at least two different fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; or a lipid backbone having a single isotopically-labeled fatty acid at a first position on the lipid backbone and having a mixture of at least two different fatty acids at a separate position on the lipid backbone, where
- a kit comprising: i) one or more mixtures of lipid molecules for use as an internal standard, wherein each of the one or more mixtures of lipid molecules is representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising one or more of: a lipid backbone having a mixture of at least two different isotopically-labeled fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; an isotopically-labeled lipid backbone having a mixture of at least two different fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; or a lipid backbone having a single isotopically-labeled fatty acid at a first position on the lipid backbone and having a mixture of
- a method for one of detecting and quantifying lipid molecules present in a sample of interest comprising: i) adding to a sample of interest a known amount of a composition having one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in the sample of interest, the composition comprising one or more of: a) a lipid backbone having a mixture of at least two different isotopically-labeled fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; b) an isotopically-labeled lipid backbone having a mixture of at least two different fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; or c) a lipid backbone having a single isotopically-labeled
- FIG. 1 is a schematic of a phospholipid showing a general strategy for producing phospholipid internal standards according to one or more embodiments of the present disclosure.
- FIG. 2A-2C show the structure of phosphatidylcholine (PC) internal standards according to one or more embodiments of the present disclosure.
- PC phosphatidylcholine
- FIG. 3 shows the structure of a lysophosphatidylcholine (LPC) internal standard according to one or more embodiments of the present disclosure.
- LPC lysophosphatidylcholine
- FIG. 4A-4C show the structure of phosphatidylethanolamine (PE) internal standards according to one or more embodiments of the present disclosure.
- PE phosphatidylethanolamine
- FIG. 5 shows the structure of a lysophosphatidylethanolamine internal standard according to one or more embodiments of the present disclosure.
- FIG. 6A-6C show the structure of sphingomyelin internal standards according to one or more embodiments of the present disclosure.
- A deuterium-labeled sphingosine at the first position, and the fatty acid "R" in the sn-2 position
- B the exemplary fatty acid palmitate (16:0) in the sn-2 position
- C four exemplary fatty acids for acylating into the sn-2 position.
- FIG. 7A-7C show the structure of triacylglycerol internal standards according to one or more embodiments of the present disclosure .
- A deuterium-labeled palmitate (16:0) at the sn-1 position, oleate (18:ln9) at the sn-2 position, and the fatty acid "R” in the sn-3 position
- B the exemplary fatty acid palmitate (16:0) in the sn-3 position
- C eight exemplary fatty acids for acylating into the sn-3 position.
- FIG. 8A-8C show the structure of diacylglycerol internal standards according to one or more embodiments of the present disclosure.
- A deuterium-labeled palmitate (16:0) at the sn- 1 position, and the fatty acid "R" in the sn-2 position
- B the exemplary fatty acid palmitate (16:0) in the sn-2 position
- C eight exemplary fatty acids for acylating into the sn-2 position.
- FIG. 9A-9C show the structure of cholesteryl ester internal standards according to one or more embodiments of the present disclosure.
- FIG. 10A-10B show the structures of exemplary free fatty acids according to one or more embodiments of the present disclosure.
- FIG. 11 is a graph showing the actual concentrations of the indicated
- phosphatidylcholine species in an unlabeled internal standard mix sample compared to the concentrations calculated using a traditional internal standard (IS) PC17:0/17:0 and an exemplary IS mix according to one or more embodiments of the present disclosure.
- IS traditional internal standard
- FIG. 12 is a graph showing the concentration calculated using the internal standard mixture and the precision of the calculations (in %CV) for 15 human serum samples according to one or more embodiments of the present disclosure.
- FIG. 13 shows box plots of the total concentration of the cholesteryl ester (CE) lipid class, calculated using the internal standard mixture, for 15 human serum samples run in triplicate according to one or more embodiments of the present disclosure.
- FIG. 14 shows box plots of the total concentration of the triacylglycerol (TAG) lipid class, calculated using the internal standard mixture, for 15 human serum samples run in triplicate according to one or more embodiments of the present disclosure.
- TAG triacylglycerol
- FIG. 15A-15C are plots showing the total concentrations of (A) cholesteryl ester
- CE phosphatidylcholine
- PE phosphatidylethanolamine
- FIG. 16 is a plot showing the relative amount of the 22 fatty acids measured in the cholesteryl ester (CE) lipid class calculated using a single internal standard and multiple internal standards according to one or more embodiments of the present disclosure.
- FIG. 17A-17D show the concentrations of exemplary polyunsaturated fatty acids in the phosphatidylcholine (PC) or cholesteryl ester (CE) lipid classes calculated using a single internal standard and multiple internal standards according to one or more embodiments of the present disclosure.
- PC phosphatidylcholine
- CE cholesteryl ester
- Lipids are problematic targets for quantification by internal standards because they have a diverse array of chemical properties, even within a given lipid class.
- the lipids also have combinatorial complexity, for example, several of many potential fatty acids are acylated onto one of a dozen or so backbones.
- What is needed is a way to make a set of internal standards that (1) represents the chemical diversity of complex lipids and (2) creates a mixture of these standards in a relative abundance, representing the expected composition of lipids in a sample, which makes the compounds useful as internal standards.
- the presently disclosed subject matter provides methods and compositions for internal standards that are representative of the chemical diversity of complex lipids.
- lipid metabolites or otherwise referred to herein as “lipid molecules”
- fatty acids labeled with a prefix "CE”, “DG”, “FA”, “PC”, “PE”, “LPC”, “LPE”, “O-PC”, “P-PE”, “SM”, “TG”, or “CER” refer to the indicated fatty acids present within cholesteryl esters, diacylglycerols (diglycerides), free fatty acids,
- phosphatidylcholines phosphatidylcholines, phosphatidylethanolamines, lysophosphatidylcholines,
- the indicated fatty acid components are quantified as a proportion of total fatty acids within the lipid class indicated by the prefix.
- References to fatty acids without a prefix or other indication of a particular lipid class generally indicate fatty acids present within total lipids in a sample.
- LC LC
- CE concentration of lipids of that class expressed as nMoles per gram of serum or plasma
- PC 18:2n6 indicates the percentage of plasma or serum phosphatidylcholine comprised of linoleic acid (18:2n6)
- TGLC indicates the absolute amount (e.g., in nMoles per gram) of triglyceride present in plasma or serum.
- MUFA monounsaturated fatty acid, polyunsaturated fatty acid, and saturated fatty acid, respectively.
- lipid backbone refers to the portion of the lipid molecule that excludes the fatty acid groups or acyl groups.
- fatty acids and “acyl groups” are used interchangeably.
- lipid molecular species or “molecular species” refers to a lipid molecule comprised of a specific fatty acid or acyl group attached to a specific lipid backbone (e.g., PC 18:2n6, CE 16:ln6, etc.).
- isotopically labeled refers to an internal standard or any portion of an internal standard marked for determination using any suitable moiety (e.g., deuterium ( H,
- any atom or any number of atoms of the internal standard may be labeled with the isotope.
- the isotope may be deuterium, and the internal standard may contain 9 deuterium atoms.
- the isotope may be deuterium and the internal standard may contain 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 31 deuterium atoms.
- One use of the methods described herein is for calibrating or aiding in calibrating mass spectrometry instruments or multiple mass spectrometry instruments run in tandem (i.e., a "platform").
- a platform two types of calibration are required: one for lipid class concentrations and one for fatty acid composition of the class.
- the results of the platform calibration may be computationally calibrated using either the control samples or comparison to a quantitative database of results.
- lipid class as used herein is meant to refer to a class of lipid including, for example, triacylglycerols, diacylglycerols, cholesteryl esters, free fatty acids, phosphatidylcholine, o-phosphatidylcholine, phosphatidylethanolamine, p- phosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylethanolamine, sphingomyelin, cardiolipin, phosphatidylserine, lysophosphatidylserine, phosphatidylinositol, lysophosphatidylinositol, phosphatidylglycerol, lysophosphatidylglycerol, phosphatidic acid, lysophosphatidic acid, CDP-d
- lactosylceramide lactosylceramide, glucosylceramide, phytoceramide, 6-hydroxyceramide, cerebroside, ganglioside, wax esters, wax diesters, and 1-monoacylglycerol.
- the triacylglycerols, diacyl glycerols, cholesteryl esters, free fatty acids are broadly as neutral lipids.
- phosphatidylcholine, o-phosphatidylcholine, phosphatidylethanolamine, p- phosphatidylethanolamine, lysophosphatidylcholine, lysophosphatidylethanolamine, sphingomyelin, cardiolipin, phosphatidylserine, lysophosphatidylserine, phosphatidylinositol, lysophosphatidylinositol, phosphatidylglycerol, lysophosphatidylglycerol, phosphatidic acid, lysophosphatidic acid, CDP-diacylglycerol, lyso CDP-diacylglycerol are broadly as
- the internal standard mixture may include a phospholipid wherein each phospholipid head group (e.g., PC, PE, SM) contains a) an isotopically-labeled fatty acid wherein the isotopically-labeled fatty acid is at the sn-1 or sn-2 position; and b) an acylated mixture of fatty acids, wherein the acylated mixture of fatty acids is at a separate position (i.e., the position not occupied by the isotopically-labeled fatty acid), and wherein the acylated mixture of fatty acids approximates the concentration of fatty acids in the target complex lipid.
- each phospholipid head group e.g., PC, PE, SM
- each phospholipid head group contains a) an isotopically-labeled fatty acid wherein the isotopically-labeled fatty acid is at the sn-1 or sn-2 position
- an acylated mixture of fatty acids wherein the acylated mixture of
- the isotopically-labeled fatty acid is a saturated fatty acid
- the acylated mixture of fatty acids is a pre-defined mixture of unsaturated and polyunsaturated fatty acids.
- the isotopically-labeled saturated fatty acid is palmitate (16:0) at the sn-1 position
- the acylated mixture of unsaturated and polyunsaturated fatty acids is a pre-defined mixture at the sn-2 position.
- the acylated mixture is comprised of unsaturated fatty acids.
- the phospholipid is lysophosphatidylcholine, and the phospholipid head group contains isotopically-labeled palmitate (16:0) at the sn-1 position.
- the phospholipid is lysophosphatidylethanolamine, and the phospholipid head group contains isotopically-labeled stearate (18:0) at the sn-1 position.
- the method for producing the mixture of fatty acids is as follows: 1) determine the concentration of fatty acids in the given sample type, the concentration may be already known or may be determined by fatty acid composition analysis; 2) select a fatty acid from one or more representative degrees of unsaturation (e.g., monoene, diene, triene, tetraene, pentaene, hexaene), wherein the most abundant fatty acid in the lipid class is selected; 3) based upon the concentration of the fatty acid in the sample type, assign each fatty acid in the mixture as "high” or "low” abundance; 4) assign a percentage value of the mixture corresponding to the high and low abundance (e.g., a fatty acid with "high” abundance would comprise 20% of the mixture and a fatty acid with "low” abundance would comprise 5%); and 5) for the remaining percentage of the mixture, determine the most abundant fatty acids among unsaturated fatty acids and assign a high or low abundance as described above to complete the mixture.
- the internal standard mixture may include a phospholipid wherein the head group of each phospholipid class (e.g., PC, PE, SM) contains a) an unlabeled fatty acid, wherein the unlabeled fatty acid is at the sn-1 or sn-2 position; and b) a MUFA or PUFA, wherein the MUFA or PUFA is at the position not occupied by the unlabeled fatty acid.
- a phospholipid wherein the head group of each phospholipid class e.g., PC, PE, SM
- the head group of each phospholipid class e.g., PC, PE, SM
- an unlabeled fatty acid wherein the unlabeled fatty acid is at the sn-1 or sn-2 position
- a MUFA or PUFA wherein the MUFA or PUFA is at the position not occupied by the unlabeled fatty acid.
- the head group contains a) an unlabeled odd chain saturated fatty acid, wherein the unlabeled odd chain saturated fatty acid is at the sn-lposition; and b) an odd chain MUFA or PUFA, wherein the odd chain MUFA or PUFA is at the sn-2 position.
- the internal standard mixture may include neutral lipids wherein the neutral lipids include mixtures of isotopically-labeled MUFA or odd-chain MUFA (e.g., 17:1, 19:1, etc.).
- a quantitative fatty acid analysis may determine the exact composition of the internal standard mixture.
- the sn-1 position of each phospholipid head group is completely labeled with a single deuterated saturated fatty acid (e.g. dl6:0), therefore the remainder of the fatty acids are present in the sn-2 position.
- A/X amount of the mixture comprised of A.
- a free fatty acid is one type of neutral lipid that may comprise the internal standard mixture.
- the free fatty acid may be any free fatty acid including, for example, a single odd-chain fatty acid (e.g. 17:1, 17:2, 17:0) and/or an isotopically-labeled fatty acid (e.g.16:0, 16:1, 17:0).
- the free fatty acid may be a MUFA or the fatty acid may be a PUFA.
- a cholesteryl ester is one type of neutral lipid that may comprise the internal standard mixture.
- the cholesteryl ester may be any cholesteryl ester including, for example a cholesteryl ester comprised of a labeled cholesterol molecule, esterified to a mixture of fatty acids representing the expected composition of cholesteryl esters in the sample (see the Table 1).
- Diacylglycerols are one type of neutral lipid that may comprise the internal standard mixture.
- the diacylglycerol may be any diacylglycerol including, for example, a single odd- chain fatty acid or an isotopically-labeled fatty acid.
- the fatty acid chains of the diacylglycerol may contain a) an isotopically-labeled fatty acid wherein the isotopically labeled fatty acid is at the sn-1 or sn-2 position (a first position); and b) an acylated mixture of fatty acids, wherein the acylated mixture of fatty acids is at a separate position (i.e., the position not occupied by the isotopically-labeled fatty acid).
- the isotopically-labeled fatty acid is a saturated fatty acid.
- the isotopically-labeled fatty acid is palmitate (16:0) at the first position, and the acylated mixture of fatty acids is at the separate position and may comprise 16:0, 18:0, 18:ln9, 18:2n6, 18:3n3, 20:4n6, 20:5n3, and 22:6n3.
- the isotopically-labeled fatty acid is palmitate (16:0) at the first position and the acylated mixture of fatty acids at the separate position is a mixture of unsaturated and polyunsaturated fatty acids. .
- the fatty acid chains of the diacylglycerol in the internal standard mixture may contain a) an unlabeled odd chain saturated fatty acid, wherein the unlabeled odd chain saturated fatty acid is at the first position; and b) an odd chain MUFA or PUFA, wherein the odd chain MUFA or PUFA is at the separate position.
- the diacylglycerol in the internal standard mixture may use multiple homogenous internal standards (e.g. DG17:0/17:0 and DG17: 1/17:1).
- a triacylglycerol is one type of neutral lipid that may comprise the internal standard mixture.
- the triacylglycerol may be any triacylglycerol including, for example, a mixture of an odd-chain fatty acid and/or an isotopically-labeled fatty acid to make a mixed standard.
- the fatty acid chains of the triacylglycerol may contain a) a labeled fatty acid at one position; b) an unlabeled fatty acid at a separate position; and c) an acylated mixture of fatty acids at another separate position.
- the labeled fatty acid may be a saturated fatty acid
- the unlabeled fatty acid may be an unsaturated fatty acid.
- the label may be a deuterium label.
- the fatty acid chains of the triacylglycerol in the internal standard mixture contain a) isotopically-labeled palmitate (16:0) at one position (e.g., the sn-1 position); b) oleate (18:ln9) at a separate, or second, position (e.g., the sn-2 position); and c) an acylated mixture of fatty acids at another separate, or third, position (e.g., the sn-3 position).
- the acylated mixture of fatty acids at the third (e.g., sn-3) position may comprise, for example, 16:0, 18:0, 18:ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6 and 22:6n3.
- the internal standard mixture may comprise: a) phosphatidylcholine lipid class with isotopically-labeled palmitate (16:0) in the sn-1 position and a mixture of MUFA and PUFA in the sn-2 position; b) phosphatidylethanolamine lipid class with isotopically-labeled palmitate (16:0) or stearate (18:0) in the sn-1 position, and a mixture of MUFA and PUFA in the sn-2 position; c) lysophosphatidylcholine lipid class with isotopically-labeled palmitate (16:0) in the sn-1 position; d) lysophosphatidylethanolamine lipid class with isotopically-labeled palmitate (16:0) or stearate (18:0) in the sn-1 position; e) sphingomyelin lipid class with an isotopically- labeled sphingoid backbone and
- the ceramide lipid class may be comprised of the following sphingolipid backbones: sphingosine, dihydrosphingosine, phytosphingosine, or 6- hydroxysphingosine.
- reagents described herein may be combined as an article of manufacture, for example, as a kit.
- each class is defined by the head group moiety on the lipid (e.g. PC has a phosphocholine headgroup, CE has a cholesterol headgroup).
- head group moiety on the lipid e.g. PC has a phosphocholine headgroup, CE has a cholesterol headgroup.
- fatty acids have diverse chemical structures, each lipid class is comprised of a large number of diverse components which results in distinct lipid molecular species.
- lipidomic strategies which typically use only a single internal standard per broad lipid class (e.g., phospholipids)
- methods are provided for synthesizing internal standards containing a mixture of fatty acids (up to 10 fatty acids per lipid class).
- the fatty acids in the internal standard mixture are selected to represent the diversity of chemical structures (lipid molecular species) found in the lipid classes present in the sample type to be analyzed.
- Table 1 shows the concentration of each fatty acid measured for each corresponding lipid class according to the methods of the present disclosure, and the remaining fatty acids in each lipid class were assigned to the closest internal standard analogue and assigned that measured value; the total concentration for each lipid class was calculated by adding the values (measured and assigned) of all molecular species for that lipid class.
- internal standards are provided for each of 10 lipid classes according the composition of fatty acids shown in Table 1.
- the lipid classes for the internal standards are shown in the first row of Table 1, and the fatty acid "R" groups are listed in column 1 of Table 1.
- “d” refers to the addition of a deuterium label.
- 16:0-d9 refers to palmitate with 9 deuterium atoms added
- exemplary internal standard components are provided for phosphatidylcholine and o-phosphatidylcholine, and the composition of fatty acids at the sn-2 position (sn-2 fatty acids) for these internal standards are displayed in Table 2.
- Table 2 The structures of phosphatidylcholine and sn-2 fatty acids comprising the mixture are shown in FIG. 2.
- FIG. 2A The structure of phosphatidylcholine with deuterated palmitate (16:0) in the sn-1 position and a fatty acid, denoted by "R”, in the sn-2 position is shown in FIG. 2A.
- FIG. 2B The structures of ten fatty acids (16: ln7, 18: ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6, 20:5n3, 22:4n6, 22:5n3, 22:6n3) in the fatty acid mixture for acylating into the sn-2 position of phosphatidylcholine are shown in FIG. 2C.
- Table 2 Composition of sn-2 fatty acids for phosphatidylcholine and o-phosphatidylcholine internal standards
- FIG. 4 The structure of phosphatidylethanolamine with deuterated stearate (18:0) in the sn-1 position and the fatty acid, denoted by "R", in the sn-2 position is shown in FIG. 4A.
- FIG. 4B The structures of eight fatty acids (18:ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6, 20:5n3, 22:5n3, 22:6n3) in the fatty acid mix for acylating into the sn-2 position of phosphatidylethanolamine are shown in FIG. 4C.
- Table 3 Composition of sn-2 fatty acids for phosphatidylethanolamine and p-
- exemplary internal standards are provided for
- exemplary internal standards are provided for sphingomyelin and the composition of fatty acids are displayed in Table 4.
- the structures of sphingomyelin and sn-2 fatty acids comprising the mixture are shown in FIG. 6.
- the structure of sphingomyelin with deuterium-labeled sphingosine at the first position, and the fatty acid, denoted by "R", in the sn-2 position is shown in FIG. 6A.
- the structure of sphingomyelin with deuterium-labeled sphingosine at the first position, and palmitate (16:0), as an exemplary fatty acid, in the sn-2 position is shown in FIG. 6B.
- exemplary internal standards are provided for triacylglycerol and the composition of sn-3 fatty acids are listed in Table 5.
- Table 5 The structures of triacylglycerol and sn- 3 fatty acids comprising the mixture are shown in FIG. 7.
- the structure of triacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, oleate (18:ln9) at the sn-2 position, and the fatty acid "R" in the sn-3 position is shown in FIG. 7A.
- FIG. 7B The structure of triacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, oleate (18:ln9) at the sn-2 position, and palmitate (16:0) as an exemplary fatty acid in the sn-3 position is shown in FIG. 7B.
- the structures of eight fatty acids (16:0, 18:0, 18:ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6, 22:6n3) in the fatty acid mix for labeling the sn-3 position of triacylglycerol are shown in FIG. 7C.
- exemplary internal standards are provided for diacylglycerol and the composition of sn-2 fatty acids are listed in Table 6.
- Table 6 The structures of diacylglycerol and sn-2 fatty acids comprising the mixture are shown in FIG. 8.
- the structure of diacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, and a fatty acid, denoted by "R", in the sn-2 position is shown in FIG. 8A.
- the structure of diacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, and palmitate (16:0), as an exemplary fatty acid, in the sn-2 position is shown in FIG. 8B.
- exemplary internal standards are provided for cholesteryl ester and the composition of fatty acids is listed in Table 7.
- Table 7. The structures of cholesteryl ester and fatty acids comprising the mixture are shown in FIG. 9.
- the structure of cholesteryl ester with deuterium labels at the n6 position, and the fatty acid "R" acylated to the hydroxyl group is shown in FIG. 9A.
- the structure of cholesteryl ester with deuterium labels at the n6 position, and linoleate (18:2n6), as the exemplary fatty acid, acylated to the hydroxyl group is shown in FIG. 9B.
- exemplary internal standards are provided for free fatty acids and the composition of fatty acids are listed in Table 8.
- the structures of the free fatty acids comprising the mixture are shown in FIG. 10.
- the structure of the free fatty acid palmitate (16:0) with deuterium labels is shown in FIG. 10A.
- the structure of the free fatty acid, 17:ln7, is shown in FIG. 10B.
- a method for synthesizing one or more mixtures of lipid molecules for use as an internal standard representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest comprising one or more of: attaching a mixture of at least two different isotopically-labeled fatty acids to a lipid backbone at a single position through an acylation reaction for a lipid class having at least one acyl group; attaching a mixture of at least two different fatty acids to an isotopically-labeled lipid backbone at a single position through an acylation reaction for a lipid class having at least one acyl group; or attaching a single isotopically-labeled fatty acid to a lipid backbone at a first position through an acylation reaction for a lipid class having at least two fatty acids and attaching a mixture of at least two different fatty acids to a separate position on the lipid backbone through an
- the corresponding lipid class can include one or more of triacyl glycerols, diacylglycerols, 1- monoacylglycerol, phospholipids, phosphatidylcholine, o-phosphatidylcholine,
- lysophosphatidylinositol lysophosphatidylglycerol
- lysophosphatidic acid lyso CDP- diacylglycerol
- CDP-diacylglycerol sphingomyelin
- cardiolipin phosphatidylserine
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- a method for synthesizing one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, the method comprising: attaching an isotopically-labeled fatty acid at a first position on a lipid backbone through an acylation reaction for a lipid class having at least two acyl groups; and attaching a mixture of at least two different fatty acids to the lipid backbone at a separate position through an acylation reaction, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecules present in the corresponding lipid class in the sample of interest.
- the one or more lipid classes having at least two acyl groups can include
- triacylglycerols triacylglycerols, diacyl glycerols, phospholipids, phosphatidylcholine, o-phosphatidylcholine, phosphatidyletanolamine, p-phosphatidylethanolamine, sphingomyelin, cardiolipin,
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, or Table 6.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, or Table 6.
- a method for synthesizing one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, the method comprising: attaching a mixture of at least two different fatty acids to an isotopically-labeled lipid backbone at a single position through an acylation reaction for a lipid class having at least one acyl group, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecules present in the one corresponding lipid class in the sample of interest.
- the one or more lipid classes having at least one acyl group can comprise triacylglycerols, diacyl glycerols, 1-monoacyl glycerol, phospholipids, phosphatidylcholine, o- phosphatidylcholine, phosphatidylethanolamine, p-phosphatidylethanolamine, cholesteryl esters, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylserine,
- lysophosphatidylinositol lysophosphatidylglycerol
- lysophosphatidic acid lyso CDP- diacylglycerol
- CDP-diacylglycerol sphingomyelin
- cardiolipin phosphatidylserine
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the sample of interest can be a complex mixture comprised of lipid molecules, a biological sample such as a plant sample or an animal sample.
- the animal sample may be from a mammal such as, for example, a human, a mouse, a non- human primate, a rabbit or other mammal, or a non-mammal sample such as, for example, a zebra fish sample.
- the biological sample of interest can include blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid, a tissue sample, a cellular sample, or a skin sample.
- the methods can further include performing quantitative fatty acid analysis to quantify the amount of each of the fatty acids in the mixture.
- the fatty acid can be a saturated fatty acid.
- the isotopic label can include any isotopic label including 2 H, 13 C, or 15 N.
- the first position on the lipid backbone can be a sn-1 position.
- the first position on the lipid backbone can be a sn-1 position and the separate position on the lipid backbone can be a sn-2 or a sn-3 position.
- the first position on the lipid backbone can be a sn-2 position.
- the first position can be a sn-2 and the separate position can be a sn-1 or sn-3 position.
- the first position on the lipid backbone can be a sn-3 position.
- the first position can be a sn-3 position and the separate position can be a sn-1 or sn-2 position.
- the one or more lipid classes having at least two acyl groups can consist of phosphatidylcholines or o-phosphatidylcholines, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or wherein the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein a deuterium-labeled hexadecanoyl-d9 (16:0-d9) can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise 9Z-hexadecenoyl (16:ln7), 9Z- octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,15Z-octadecatrienoyl (18:3n3), 8Z,l lZ,14Z-eico
- the one or more lipid classes having at least two acyl groups can consist of phosphatidylethanolamines and p-phosphatidylethanolamines, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or wherein the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein a deuterium-labeled octadecanoyl-d9 (18:0-d9) can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,15Z-octadecatrienoyl (18:3n3), 8Z,11Z,14Z- eicosatrienoyl (20:3n6), 5Z,8Z
- the one or more lipid classes having at least two acyl groups can consist of sphingomyelins, wherein deuterium-labeled sphingosine can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise hexadecanoyl (16:0), 9Z-octadecenoyl (18:ln9), tetracosanoyl (24:0), and 15Z-tetracosenoyl (24:ln9).
- the mixture of fatty acids at the separate position can be present at the ratios shown in Table 4.
- the one or more lipid classes having at least two acyl groups can consist of diacyl glycerols, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or wherein the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein deuterium-labeled palmitate (16:0-d9) can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise hexadecanoyl (16:0), octadecanoyl (18:0), 9Z-octadecenoyl (18:ln9), 9Z,12Z- octadecadienoyl (18:2n6), 9Z,12Z,15Z-octadecatrienoyl (18:3n3), 5Z,8Z,11Z,14Z- eicosatetraenoyl (20:4n
- the one or more lipid classes having at least two acyl groups can consist of triacylglycerols, wherein the first position can be a sn-1 position and the separate position can be a sn-2 or sn-3 position, or wherein the first position can be an sn-2 position and the separate position can be an sn-1 or sn-3 position, or wherein the first position can be a sn-3 position and the separate position can be a sn-1 or sn-2 position, wherein deuterium-labeled palmitate (16:0-d9) can be present at the first position, wherein oleate (18:ln9) can be present at one separate position, and wherein the mixture of fatty acids at another separate position can comprise hexa
- the one or more lipid classes having at least one acyl group can consist of cholesteryl esters, wherein the single position can be a hydroxyl group, and wherein the mixture of fatty acids attached to the hydroxyl group can comprise hexadecanoate (16:0), 9Z-hexadecenoate (16:ln7), 9Z-octadecenoate (18:ln9), 9Z,12Z-octadecadienoate (18:2n6), 8Z,l lZ,14Z-eicosatrienoate (20:3n6), 5Z,8Z,l lZ,14Z-eicosatetraenoate (20:4n6), 5Z,8Z,l lZ,14Z,17Z-eicosapentaenoate (20:5n3), and 4Z,7Z,10Z,13Z,16Z,19Z- docosahexaenoate (22:6n
- compositions for use as lipid internal standards for use as lipid internal standards
- a composition for use as an internal standard comprising one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising one or more of: a lipid backbone having a mixture of at least two different isotopically-labeled fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; an isotopically-labeled lipid backbone having a mixture of at least two different fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; or a lipid backbone having a single isotopically-labeled fatty acid at a first position on the lipid backbone and having a mixture of at least two different fatty acids at a separate position on the lipid backbone, where
- lysophosphatidylinositol lysophosphatidylglycerol
- lysophosphatidic acid lyso CDP- diacylglycerol
- CDP-diacylglycerol sphingomyelin
- cardiolipin phosphatidylserine
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- a composition for use as an internal standard comprising one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising: a lipid backbone having an isotopically-labeled fatty acid at a first position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least two acyl groups; and a mixture of at least two different fatty acids present at a separate position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecular species present in the corresponding lipid class in the sample of interest.
- the lipid class can include one or more of triacylglycerols, diacyl glycerols, phospholipids, phosphatidylcholine, o-phosphatidylcholine, phosphatidylethanolamine, p-phosphatidylethanolamine, sphingomyelin, cardiolipin, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, CDP- diacylglycerol, ceramide, lactosylceramide, glucosylceramide, phytoceramide, 6- hydroxyceramide, cerebroside, ganglioside, or wax diesters.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, or Table 6.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, or Table 6.
- a composition for use as an internal standard comprising one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising: a lipid backbone having one or more isotopic labels, wherein the lipid backbone is for a lipid class having at least one acyl group; and a mixture of at least two different fatty acids present at a single position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acids in the lipid molecular species present in the corresponding lipid class in the sample of interest.
- the lipid class can include one or more of triacylglycerols, diacylglycerols, 1-monoacylglycerol, phospholipids, phosphatidylcholine, o-phosphatidylcholine, phosphatidylethanolamine, p- phosphatidylethanolamine, cholesteryl esters, lysophosphatidylcholine,
- lysophosphatidylglycerol lysophosphatidic acid
- CDP-diacylglycerol CDP-diacylglycerol
- sphingomyelin cardiolipin
- phosphatidylserine phosphatidylinositol
- phosphatidylglycerol phosphatidic acid
- ceramide lactosylceramide
- glucosylceramide phytoceramide
- 6- hydroxyceramide cerebroside
- ganglioside wax esters, or wax diesters.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the sample of interest can be a complex mixture comprised of lipid molecules, a biological sample such as a plant sample or an animal sample.
- the animal sample may be from a mammal such as, for example, a human, a mouse, a non- human primate, a rabbit or other mammal, or a non-mammal such as, for example, a zebra fish sample.
- the biological sample of interest can include blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid, a tissue sample, a cellular sample, or a skin sample.
- the isotopic label can include any isotopic label including 2 H, 13 C, or 15 N.
- the fatty acid can be a saturated fatty acid.
- the first position on the lipid backbone can be a sn-1 position.
- the first position on the lipid backbone can be a sn-1 position and the separate position on the lipid backbone can be a sn-2 or a sn-3 position.
- the first position on the lipid backbone can be a sn-2 position.
- the first position can be a sn-2 and the separate position can be a sn-1 or sn-3 position.
- the first position on the lipid backbone can be a sn-3 position.
- the first position can be a sn-3 position and the separate position can be a sn-1 or sn-2 position.
- one of the lipid classes can consist of phosphatidylcholines or o-phosphatidylcholines, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein a deuterium-labeled hexadecanoyl-d9 (16:0- d9) can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise 9Z-hexadecenoyl (16:ln7), 9Z-octadecenoyl (18:ln9), 9Z,12Z- octadecadienoyl (18:2n6), 9Z,12Z,15Z-octadecatrienoyl (18:3n3), 8Z,l lZ,14Z-eicosatrienoyl (20:3
- one of the lipid classes can consist of phosphatidylethanolamines and p-phosphatidylethanolamines, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein a deuterium-labeled
- octadecanoyl-d9 (18:0-d9) can be present at the first position , and wherein the mixture of fatty acids at the separate position can comprise 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,15Z-octadecatrienoyl (18:3n3), 8Z,l lZ,14Z-eicosatrienoyl (20:3n6),
- one of the lipid classes can consist of sphingomyelins, wherein deuterium-labeled sphingosine can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise hexadecanoyl (16:0), 9Z- octadecenoyl (18:ln9), tetracosanoyl (24:0), and 15Z-tetracosenoyl (24:ln9).
- the mixture of fatty acids at the separate position can be present at the ratios shown in Table 4.
- one of the lipid classes can consist of diacyl glycerols, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein deuterium-labeled palmitate (16:0-d9) can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise hexadecanoyl (16:0), octadecanoyl (18:0), 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,15Z- octadecatrienoyl (18:3n3), 5Z,8Z,l lZ,14Z-eicosatetraenoyl (20:4n6), 5Z,8Z,11
- one of the lipid classes can consist of triacylglycerols, wherein the first position can be a sn-1 position and the separate position can be a sn-2 or sn-3 position, or the first position can be a sn-2 position and the separate position can be a sn-1 or sn-3 position, or the first position can be a sn-3 position and the separate position can be a sn-1 or sn-2 position, wherein deuterium-labeled palmitate (16:0-d9) can be present at the first position, wherein oleate (18:ln9) can be present at a sn-2 position, and wherein the mixture of fatty acids at the separate position can comprise hexadecanoyl (16:0), octadecanoyl (18:0), 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n
- one of the lipid classes can consist of cholesteryl esters, wherein the single position can be a hydroxyl group, and wherein the mixture of fatty acids attached to the hydroxyl group can comprise hexadecanoate (16:0), 9Z-hexadecenoate (16:ln7), 9Z-octadecenoate (18:ln9), 9Z,12Z-octadecadienoate (18:2n6), 8Z,11Z,14Z- eicosatrienoate (20:3n6), 5Z,8Z,l lZ,14Z-eicosatetraenoate (20:4n6), 5Z,8Z,11Z,14Z,17Z- eicosapentaenoate (20:5n3), and 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoate (22:6n3).
- a method for one of detecting and quantifying lipid molecules present in a sample of interest comprising: i) adding to a sample of interest a known amount of a composition having one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in the sample of interest, the composition comprising one or more of: a) a lipid backbone having a mixture of at least two different isotopically-labeled fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; b) an isotopically-labeled lipid backbone having a mixture of at least two different fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; or c) a lipid backbone having a single isotopically-labeled
- a method for one of detecting and quantifying lipid molecules present in a sample of interest comprising: adding to a sample of interest a known amount of a composition having one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in the sample of interest, wherein each mixture of lipid molecules comprises i) a lipid backbone having an isotopically-labeled fatty acid at a first position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least two acyl groups; and ii) a mixture of at least two different fatty acids present at a separate position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acid in the lipid molecular species present
- a method for one of detecting and quantifying lipid molecules present in a sample of interest comprising: adding to a sample of interest a known amount of a composition having one or more mixtures of lipid molecules representative of the composition of lipid molecular species present in one or more corresponding lipid classes in the sample of interest, wherein each mixture of lipid molecules comprises i) a lipid backbone having one or more isotopic labels, wherein the lipid backbone is for a lipid class having at least one acyl group; and ii) a mixture of at least two different fatty acids present at a single position on the lipid backbone, wherein the mixture of fatty acids is representative of the fatty acids that occur in the corresponding lipid class in the sample of interest, and wherein each of the fatty acids in the mixture is present at a ratio representative of the ratio of occurrence of the fatty acids in the lipid molecular species present in the
- the method of detecting and/or quantifying the lipid molecular species present in the sample of interest can include one or a combination of mass spectrometry (MS), high performance liquid chromatography (HPLC), isocratic HPLC, gradient HPLC, normal phase chromatography, reverse phase HPLC, size exclusion chromatography, ion exchange chromatography, capillary electrophoresis, microfluidics, chromatography, gas chromatography (GC), thin-layer chromatography (TLC), and combinations thereof.
- the method for detecting and/or quantifying the lipid molecular species present in the biological sample can include the use of mass spectrometry (MS).
- the sample of interest can be a complex mixture comprised of lipid molecules, a biological sample such as a plant sample or an animal sample.
- the animal sample may be from a mammal such as, for example, a human, a mouse, a non-human primate, a rabbit or other mammal, or a non-mammal such as, for example, a zebra fish sample.
- the biological sample of interest can include blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid, a tissue sample, a cellular sample, or a skin sample.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- the one or more mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, or Table 7.
- kits of the present disclosure include one or more internal standards and instructions for using the internal standards to detect and/or quantify lipids in the sample of interest.
- the kit may further include one or more control samples and sample collection receptacles.
- the internal standard compositions within a kit can be packaged together in various combinations of one or more lipid classes or can be packaged in separate vials or containers.
- a kit may include labels and/or packaging inserts setting out instructions for preparation and use, specimen collection receptacles, a transportation container, and/or a mailer for shipping.
- kit components in separate packaging could include buffers and other reagents for the detection and/or quantification of lipids in a sample of interest.
- the kit can comprise one or more internal standard mixtures.
- the kit can contain an internal standard mixture comprising isotopically labeled fatty acids wherein at least one isotopically labeled fatty acid is present from each lipid class in the sample of interest.
- the kit may contain a set of internal standards comprising the lipid classes and isotopically labeled fatty acids presented in Table 1.
- the isotopically labeled fatty acids in the set of internal standards are present at the ratios given in Table 1.
- the kit may further comprise a volumetric container.
- the volumetric container may be any container (i.e., a cup, vial, microfuge tube, microtiter plate etc.) suitable for holding a liquid sample.
- the volumetric container may optionally contain volumetric measurements which may be useful in measuring out a desirable amount of the sample or other reagents.
- the volumetric container may be made of any material (e.g., plastics, aluminum, stainless steel).
- the internal volume of the volumetric container depends on the type of sample to be collected.
- the volumetric container can include a body and a cap. In some embodiments, the internal standard material may be attached to the cap. In some embodiments, the internal standard material may be coated on the internal volume of the body of the volumetric container.
- the volumetric container may additionally be configured for the type of sample collection contemplated and used for collection of the specimen.
- a specimen collection receptacle is separately provided in the kit, and may be in the form of a cup, vial, microfuge tube.
- the kit may optionally comprise a transportation container.
- the transportation container may be any structure suitable for transportation of samples.
- the container is configured such that the sample material can be packed into the container and the container may be sealed.
- the kit may optionally include an extraction solution.
- a kit comprising: i) one or more mixtures of lipid molecules for use as an internal standard, wherein each of the one or more mixtures of lipid molecules is representative of the composition of lipid molecular species present in one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising one or more of: a lipid backbone having a mixture of at least two different isotopically-labeled fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; an isotopically-labeled lipid backbone having a mixture of at least two different fatty acids at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group; or a lipid backbone having a single isotopically-labeled fatty acid at a first position on the lipid backbone and having a mixture of
- lysophosphatidylinositol lysophosphatidylglycerol
- lysophosphatidic acid lyso CDP- diacylglycerol
- CDP-diacylglycerol sphingomyelin
- cardiolipin phosphatidylserine
- phosphatidylinositol phosphatidylglycerol, phosphatidic acid, ceramide, lactosylceramide, glucosylceramide, phytoceramide, 6-hydroxyceramide, cerebroside, ganglioside, wax esters, or wax diesters.
- a kit comprising: i) one or more mixtures of lipid molecules for use as an internal standard, wherein each of the one or more mixtures of lipid molecules is representative of the composition of lipid molecular species present in each of one or more corresponding lipid classes in a sample of interest, each mixture of lipid molecules comprising: a lipid backbone having an isotopically-labeled fatty acid at a first position on the lipid backbone and a mixture of at least two different fatty acids present at a separate position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least two acyl groups, or a lipid backbone having one or more isotopic labels and a mixture of at least two different fatty acids present at a single position on the lipid backbone, wherein the lipid backbone is for a lipid class having at least one acyl group, wherein the mixture of fatty acids is representative of the fatty acids that occur in the lipid
- the lipid class having at least one acyl group can include one or more of triacylglycerols, diacylglycerols, phospholipids, phosphatidylcholine, o-phosphatidylcholine,
- phosphatidylserine phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, CDP- diacylglycerol, ceramide, lactosylceramide, glucosylceramide, phytoceramide, 6- hydroxyceramide, cerebroside, ganglioside, wax diesters cholesteryl esters,
- lysophosphatidylinositol lysophosphatidylglycerol
- lysophosphatidic acid lyso CDP- diacylglycerol
- wax esters 1-monoacylglycerol.
- kits can include two or more of the mixtures of the lipid molecules representative of the composition of lipid molecular species present in two or more of the corresponding lipid classes in the sample of interest.
- the two or more mixtures of the lipid molecules can be packaged as a single component.
- the two or more mixtures of the lipid molecules can be packaged as separate components.
- kits may further include reagents for the detecting and quantifying.
- kits may further include a control sample having a known concentration of the composition of the lipid molecular species.
- the kits may further include a mixture of free fatty acids for use as an internal standard that is representative of the composition of free fatty acids in the sample of interest.
- the free fatty acids for use in the kit may comprise the free fatty acids shown in Table 8.
- the sample of interest can be a complex mixture comprised of lipid molecules, a biological sample such as a plant sample or an animal sample.
- the animal sample may be from a mammal such as, for example, a human, a mouse, a non-human primate, a rabbit or other mammal, or a non-mammal such as, for example, a zebra fish sample.
- the biological sample of interest can include blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid, a tissue sample, a cellular sample, or a skin sample.
- the fatty acid can be a saturated fatty acid.
- the isotopic label can include 2 H, 13 C, or 15 N.
- the mixtures of fatty acids in each of the one or more mixtures of lipid molecules can include the mixtures of lipid molecular species listed in one or more of Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8.
- the mixtures of fatty acids in each of the one or more mixtures of lipid molecules can consist of one or more of the mixtures of lipid molecular species listed in one or more of Table 1, Table 2, Table 3, Table 4, Table 5, Table 6, Table 7, or Table 8.
- the first position on the lipid backbone can be a sn-1 position.
- the first position on the lipid backbone can be a sn-1 position and the separate position on the lipid backbone can be a sn-2 or a sn-3 position.
- one of the lipid classes can consist of phosphatidylcholines or o- phosphatidylcholines, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein a deuterium-labeled hexadecanoyl-d9 (16:0-d9) can be present at the first position, and wherein the mixture of fatty acid groups at the separate position can comprise 9Z-hexadecenoyl (16:ln7), 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,15Z-octadecatrienoyl (18:3n3), 8Z,l lZ,14Z-eicosatrienoyl (20:3n6),
- one of the lipid classes can consist of phosphatidylethanolamines and p- phosphatidylethanolamines, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein a deuterium-labeled octadecanoyl-d9 (18:0-d9) can be present at the first position , and wherein the mixture of fatty acid groups at the separate position can comprise 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,
- one of the lipid classes can consist of sphingomyelins, wherein deuterium- labeled sphingosine can be present at the first position, and wherein the mixture of fatty acids at the separate position can comprise hexadecanoyl (16:0), 9Z-octadecenoyl (18:ln9), tetracosanoyl (24:0), and 15Z-tetracosenoyl (24:ln9).
- the mixture of fatty acid groups at the separate position can be present at the ratios shown in Table 4.
- one of the lipid classes can consist of diacylglycerols, wherein the first position can be a sn-1 position and the separate position can be a sn-2 position, or the first position can be a sn-2 position and the separate position can be a sn-1 position, wherein deuterium-labeled palmitate (16:0-d9) can be present at the first position, and wherein the mixture of fatty acid groups at the separate position can comprise hexadecanoyl (16:0), octadecanoyl (18:0), 9Z-octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9Z,12Z,15Z- octadecatrienoyl (18:3n3), 5Z,8Z,l lZ,14Z-eicosatetraenoyl (20:4n6), 5Z,8Z,l lZ,14Z-eicos
- one of the lipid classes can consist of triacylglycerols, wherein the first position can be a sn-1 position and the separate position can be a sn-2 or sn-3 position, or the first position can be a sn-2 position and the separate position can be a sn-1 or sn-3 position, or the first position can be a sn-3 position and the separate position can be a sn-1 or sn-2 position, wherein deuterium-labeled palmitate (16:0-d9) can be present at the first position, wherein oleate (18:ln9) can be present at a one separate position, and wherein the mixture of fatty acid groups at another separate position can comprise hexadecanoyl (16:0), octadecanoyl (18:0), 9Z- octadecenoyl (18:ln9), 9Z,12Z-octadecadienoyl (18:2n6), 9
- one of the lipid classes can comprise cholesteryl esters
- lysophosphatidylinositol lysophosphatidylglycerol
- lysophosphatidic acid lyso CDP- diacyl glycerol
- wax esters or 1-monoacylglycerol.
- one of the lipid classes can consist of cholesteryl esters, wherein the single position is a hydroxyl group, and wherein the mixture of acyl groups attached to the hydroxyl group comprises hexadecanoate (16:0), 9Z-hexadecenoate (16:ln7), 9Z-octadecenoate (18:ln9), 9Z,12Z-octadecadienoate (18:2n6), 8Z,l lZ,14Z-eicosatrienoate (20:3n6), 5Z,8Z,11Z,14Z- eicosatetraenoate (20:4n6), 5Z,8Z,l lZ,14Z,17Z-eicosapentaenoate (20:5n3), and
- Assays for lipid metabolite or lipid molecule content may be performed on any sample type including, for example, a body fluid sample (e.g., blood, blood plasma, urine, cerebral spinal fluid (CSF)), a tissue sample, a cellular sample, a skin sample, a solution, a complex mixture, in vitro cultured cells, and cell culture media.
- a body fluid sample e.g., blood, blood plasma, urine, cerebral spinal fluid (CSF)
- tissue sample e.g., a tissue sample, a cellular sample, a skin sample, a solution, a complex mixture, in vitro cultured cells, and cell culture media.
- the amounts of the lipid molecules are determined from sample(s) selected from the group consisting of complex mixtures of lipids, blood, plasma, serum, isolated lipoprotein fraction, saliva, urine, lymph fluid, and cerebrospinal fluid.
- the assays may be performed on whole blood, plasma, serum, or isolated lipoprotein fractions.
- multiple different lipid molecules are measured in the same sample. In other embodiments, each of multiple lipid molecules is measured from a different sample. If multiple samples are used, the samples may be from the same or different body fluids of the subject.
- lipid molecules and other biomarkers may readily be isolated and/or quantified by methods known to those of skill in the art, including, but not limited to, methods utilizing: mass spectrometry (MS), high performance liquid chromatography (HPLC), isocratic HPLC, gradient HPLC, normal phase chromatography, reverse phase HPLC, size exclusion
- the methods of the invention utilize MS to determine lipid molecule content.
- lipids were extracted by the method of Folch et al. (J Biol Chem 226:497-509) using chloroform:methanol (2:1 v/v).
- Neutral lipids were separated from polar lipids by solid phase chromatography.
- the polar lipid fraction was separated into individual lipid classes using the Agilent Technologies 1100 Series LC, and the lipid class fractions were collected for fatty acid analysis.
- Neutral lipids were separated into individual lipid classes by thin-layer chromatography using a solvent system consisting of petroleum ether/diethyl ether/acetic acid (80:20:1), and the lipid class fractions were collected for fatty acid analysis.
- Each lipid class was transesterified in 1% sulfuric acid in methanol in a sealed vial under a nitrogen atmosphere at 100°C for 45 minutes.
- the resulting fatty acid methyl esters were extracted from the mixture with hexane containing 0.05% butylated hydroxytoluene and prepared for GC analysis by sealing the hexane extracts under nitrogen.
- Fatty acid methyl esters were separated and quantified by capillary GC (Agilent Technologies 6890 Series GC) equipped with a 30 m DB 88 capillary column (Agilent Technologies) and a flame ionization detector.
- Boettcher M et al. Precision and comparability of Abuscreen OnLine assays for drugs of abuse screening in urine on Hitachi 917 with other immunochemical tests and with GC/MS. Clin Lab. 2000;46(l-2):49-52; Westermann J, et al. Simple, rapid and sensitive determination of epinephrine and norepinephrine in urine and plasma by non-competitive enzyme immunoassay, compared with HPLC method. Clin Lab. 2002;48(1-2):61-71; Aoyagi K, et al. Performance of a conventional enzyme immunoassay for hepatitis C virus core antigen in the early phases of hepatitis C infection. Clin Lab.
- TRUEMASS analytical platform may also be used for the methods of the invention.
- TRUEMASS is an analytical platform that may be used to get quantitative data from a sample on approximately 400 individual metabolites involved in structural and energetic lipid metabolism such as triglyceride, cholesterol ester and phospholipid metabolism. This platform is useful in profiling diseases as structural and energetic lipids are central components of metabolism and integrated into virtually every biological process in the body.
- a data set for a sample for example a plasma, serum or other biological sample, comprises the quantitative measurement of free cholesterol and the following fatty acids from phosphatidylcholines, phosphatidylethanolamines, lyso-phosphatidylcholines, triglycerides, diglycerides, free fatty acids, and cholesterol esters: 14:0, 15:0, 16:0, 18:0,20:0,22:0,24:0, 14:ln5, 16:ln7,
- TRUEMASS Methods for using TRUEMASS are known to those of skill in the art, and are also described in the following documents, which are herein incorporated by reference in their entirety: U.S. Patent Application No. 11/296,829 (filed 12/6/05); Mutch DM, et al. An integrative metabolism approach identifies stearoyi-CoA desaturase as a target for an arachidonate-enriched diet. FASEB J. 2005
- Watkins SM et al. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. Lipid Res. 2002 Nov;43(l l):1809-17.
- Exemplary phospholipid internal standards for phosphatidylcholine, o- phosphatidylcholine, phosphatidylethanolamine, and p-phosphatidylethanolamine were synthesized starting with a glycerol phosphate head group and acylating deuterium-labeled palmitate (16:0) in the sn-1 position; and acylating a mixture of unsaturated fatty acids in the sn- 2 position.
- phosphatidylethanolamine is represented in FIG. 1.
- sn-2 fatty acids For the exemplary internal standard components phosphatidylcholine and o- phosphatidylcholine, the composition of fatty acids at the sn-2 position (sn-2 fatty acids) are displayed in Table 2. The structures of phosphatidylcholine and sn-2 fatty acids comprising the mixture are shown in FIG. 2. The structure of phosphatidylcholine with deuterated palmitate (16:0) in the sn-1 position and a fatty acid, denoted by "R", in the sn-2 position is shown in FIG. 2A.
- FIG. 2B The structure of phosphatidylcholine with deuterated palmitate (16:0) in the sn-1 position and oleate (18:ln9), as an exemplary fatty acid, in the sn-2 position is shown in FIG. 2B.
- FIG. 2C phosphatidylcholine are shown in FIG. 2C.
- Exemplary lysophosphatidylcholine internal standards were synthesized starting with the phospholipid head group and acylating deuterium-labeled palmitate (16:0). The structure is shown in FIG. 3.
- FIG. 4 The structure of phosphatidylethanolamine with deuterated stearate (18:0) in the sn-1 position and the fatty acid, denoted by "R", in the sn-2 position is shown in FIG. 4A.
- FIG. 4B The structure of phosphatidylethanolamine with deuterated stearate (18:0) in the sn-1 position and oleate (18:ln9) as an exemplary fatty acid in the sn-2 position is shown in FIG. 4B.
- FIG. 4C The structures of eight fatty acids (18:ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6, 20:5n3, 22:5n3, 22:6n3) in the fatty acid mix for acylating into the sn-2 position of phosphatidylethanolamine are shown in FIG. 4C.
- Lysophosphatidylethanolamine internal standards were synthesized starting with the phospholipid head group and acylating deuterium-labeled stearate (18:0). The structure is shown in FIG. 5.
- Sphingomyelin internal standards were synthesized starting with a phosphocholine head group, acylating a deuterium-labeled sphingosine to the sn-1 position, and acylating a mixture of fatty acids into the sn-2 position.
- the acylated mixture of fatty acids in the sn-2 position may comprise, for example, 16:0, 18:ln9, 24:0, and 24:ln9.
- sphingomyelin For the exemplary internal standard component, sphingomyelin, the composition of fatty acids are displayed in Table 4. The structures of sphingomyelin and sn-2 fatty acids comprising the mixture are shown in FIG. 6.
- FIG. 6 The structure of sphingomyelin with deuterium-labeled sphingosine at the first position, and the fatty acid, denoted by "R", in the sn-2 position is shown in FIG. 6A.
- the structures of four fatty acids (16:0, 18:ln9, 24:0, 24:ln9) in the fatty acid mix for acylating into the sn-2 position of sphingomyelin are shown in FIG. 6C.
- Triacylglycerol internal standards were synthesized starting with a diacylglycerol backbone, acylating deuterium-labeled palmitate (16:0) at the sn-1 position, acylating oleate (18:ln9) at the sn-2 position and acylating a mixture of fatty acids into the sn-3 position.
- the acylated mixture of fatty acids at the sn-3 position may comprise, for example, 16:0, 18:0, 18:ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6 and 22:6n3.
- triacylglycerol the composition of sn-3 fatty acids are listed in Table 5.
- Table 5 The structures of triacylglycerol and sn-3 fatty acids comprising the mixture are shown in FIG. 7.
- FIG. 7A The structure of triacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, oleate (18:ln9) at the sn-2 position, and the fatty acid "R" in the sn-3 position is shown in FIG. 7A.
- FIG. 7B The structure of triacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, oleate (18:ln9) at the sn-2 position, and palmitate (16:0) as an exemplary fatty acid in the sn-3 position is shown in FIG. 7B.
- the structures of eight fatty acids (16:0, 18:0, 18:ln9, 18:2n6, 18:3n3, 20:3n6, 20:4n6, 22:6n3) in the fatty acid mix for labeling the sn-3 position of triacylglycerol are shown in FIG. 7C.
- Exemplary diacylglycerol internal standards were synthesized starting with a glycerol backbone, acylating deuterium-labeled palmitate (16:0) at the sn-1 position, and acylating a mixture of fatty acids into the sn-2 position.
- the acylated mixture of fatty acids at the sn-2 position may comprise, for example, 16:0, 18:0, 18:ln9, 18:2n6, 18:3n3, 20:4n6, 20:5n3, and 22:6n3.
- diacylglycerol the composition of sn-2 fatty acids are listed in Table 6.
- Table 6 The structures of diacylglycerol and sn-2 fatty acids comprising the mixture are shown in FIG. 8.
- the structure of diacylglycerol with deuterium-labeled palmitate (16:0) at the sn-1 position, and palmitate (16:0), as an exemplary fatty acid, in the sn-2 position is shown in FIG. 8B.
- Exemplary cholesteryl ester internal standards were synthesized starting with a cholesterol backbone, adding deuterium labels in the n6 position, and acylating a mixture of fatty acids to the hydroxyl group.
- the acylated mixture of fatty acids acylated to the hydroxyl group may comprise, for example, 16:0, 16:ln7, 18:ln9, 18:2n6, 20:3n6, 20:4n6, 20:5n3, and 22:6n3.
- cholesteryl ester the composition of fatty acids is listed in Table 7.
- Table 7 The structures of cholesteryl ester and fatty acids comprising the mixture are shown in FIG. 9.
- the structure of cholesteryl ester with deuterium labels at the n6 position, and the fatty acid "R" acylated to the hydroxyl group is shown in FIG. 9A.
- the structure of cholesteryl ester with deuterium labels at the n6 position, and linoleate (18:2n6), as the exemplary fatty acid, acylated to the hydroxyl group is shown in FIG. 9B.
- FIG. 9C The structure of eight fatty acids (16:0, 16:ln7, 18:ln9, 18:2n6, 20:3n6, 20:4n6, 20:5n3, 22:6n3) in the fatty acid mix for use in acylating the hydroxyl group of cholesteryl ester are shown in FIG. 9C.
- Free fatty acid internal standards were produced by synthesizing a 50:50 mixture consisting of 50% deuterium-labeled fatty acid and 50% single odd-chain fatty acid.
- the deuterium-labeled fatty acid may be, for example, palmitate (16:0), and the odd-chain fatty acid may be, for example, 17:ln7.
- Lipids were extracted from samples using a methanol: dichloromethane extraction procedure. Internal standards in dichloromethane: methanol (50:50) were added to the extract solution, followed by a series of centrifugation and bottom layer recovery steps. The combined bottom layer aliquots were concentrated under nitrogen and reconstituted in 0.25mL of lOmM ammonium acetate dichloromethane: methanol (50:50). The extracts were transferred to inserts and placed in vials for analysis using infusion-MS. Infusion-MS analysis is performed on a Shimazdu LC with nano PEEk tubing combined with the Sciex Selexlon and 5500 QTRAP. The samples were analyzed via both positive and negative mode electrospray. The 5500 QTRAP scan is performed in MRM mode with the total of +1100 MRMs including internal standards.
- An exemplary internal standard mixture containing the components indicated in Table 9 was synthesized, and the synthetic internal standards mixture was evaluated to determine the concentrations and purity of the mixture. Labeled and unlabeled standard mixtures were reported to be 10.3 mgs/mL. Actual concentrations of the internal standards in the mixture were determined based on NMR and quantitative fatty acid analysis; results of these two analyses were within 2% of each other. Column 2 of Table 9 indicates the target concentration for each internal standard component of the mixture, and Columns 3 and 4 of Table 9 shows the actual concentration for each indicated component. Column 3 shows the concentration obtained for the labeled standards and Column 4 shows the concentration obtained for the unlabeled standards. A complete fatty acid analysis of the samples determined that the internal standard mixture was >99 pure.
- the precision as determined by calculating the analytical CV was 20% and 11% for the traditional PC17:0/17:0 IS and the IS mixture respectively.
- the overall precision as determined by calculating the analytical CV was 11% and 3% for the traditional PC17:0/17:0 IS and the IS mixture respectively.
- the Mole% composition for the fatty acids was calculated using the IS mixture and the traditional IS and compared to the actual concentration of the fatty acids in the sample.
- the calculated values obtained with the IS mixture were closer to the actual values than those values calculated using the traditional IS. The results are graphically presented in FIG. 11.
- the lipid molecular species in 15 human serum samples, run in triplicate were measured using the mixture of internal standards described in Table 1. Lipids were extracted from the serum samples in the presence of the labeled internal standard mixture and the lipid extracts were analyzed using the described methods. The mean concentration of each of the 1,100 measured lipid molecular species in the triplicate samples was calculated using the internal standard mixture, and the precision was determined by calculating the analytical CV. The average concentration and CV values for the 15 triplicate samples were plotted for all 1,100 measured lipid molecular species. The scatterplot showing the relationship of the %CV to the concentration of lipid molecular species is graphically presented in FIG. 12. The CV was lower for lipid molecular species at the highest concentrations, however CV as low as 10% was obtained for certain molecular species at very low concentrations (e.g., 0.001 uM)..
- the average concentration of the CE lipid class from all serum samples was 3676.72, and the average CV was 1.22%. These results are presented in box plot format in FIG. 13.
- the signal which is the ratio of the concentration of CE lipid class in the serum samples to the blanks, was 1729.02.
- the average concentration of the TAG lipid class was 4105.8, and the average CV was 2.79%. These results are presented in box plot format in FIG. 14.
- the signal for the TAG lipid class was 1348.33.
- the performance of the internal standard mixture compared to a traditional internal standard was evaluated in 25 human plasma samples.
- the fatty acid composition of three exemplary lipid classes CE, PC, and PE
- CE, PC, and PE three exemplary lipid classes
- the dCE(16:0) internal standard was used for cholesteryl ester
- the dPC(16:0/18:l) internal standard was used for phosphatidylcholine
- the dPE(18:0/18:l) internal standard was used for phosphatidylethanolamine.
- fatty acids within CE, PC or PE lipid classes were assigned to the single CE, PC or PE internal standard, respectively.
- the fatty acid composition of CE, PC, and PE lipid classes was determined. All values were expressed in Mole%, a form of data that provides the relative amount of a fatty acid present in each class relative to all fatty acids.
- Mole% a form of data that provides the relative amount of a fatty acid present in each class relative to all fatty acids.
- a comparison of the fatty acid composition of cholesteryl ester (CE) for the single IS (dCE(16:0)) and multiple IS methods relative to quantitative (TrueMass) values is shown in FIG. 16.
- the polyunsaturated fatty acids appeared to be substantially biased using the single IS method.
- Specific examples of the bias against polyunsaturated fatty acids from the CE and PC lipid classes are shown below.
- the bias was calculated as described above and is presented in Table 11.
- the true (quantitative) value ( ⁇ ) and the estimated value (calculated using an internal standard) ( ⁇ ) for the exemplary fatty acids of the PC and CE lipid classes were plotted for each of the 25 plasma samples. The results are shown in FIG. 17.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580040519.5A CN107075539B (zh) | 2014-07-30 | 2015-07-30 | 用于分析结构不同的复杂脂质的方法、组合物和试剂盒 |
JP2017505546A JP6810023B2 (ja) | 2014-07-30 | 2015-07-30 | 構造的に多様な複合脂質を分析するための方法、組成物およびキット |
CA2955204A CA2955204A1 (en) | 2014-07-30 | 2015-07-30 | Methods, compositions, and kits for analysis of structurally diverse complex lipids |
EP15827995.0A EP3174991B1 (en) | 2014-07-30 | 2015-07-30 | Methods, compositions, and kits for analysis of structurally diverse complex lipids |
AU2015296304A AU2015296304B2 (en) | 2014-07-30 | 2015-07-30 | Methods, compositions, and kits for analysis of structurally diverse complex lipids |
US15/251,579 US11181535B2 (en) | 2014-07-30 | 2016-08-30 | Isotopically-labeled cholesteryl ester internal standard composition and kit |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462031099P | 2014-07-30 | 2014-07-30 | |
US62/031,099 | 2014-07-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/251,579 Continuation US11181535B2 (en) | 2014-07-30 | 2016-08-30 | Isotopically-labeled cholesteryl ester internal standard composition and kit |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016019140A1 true WO2016019140A1 (en) | 2016-02-04 |
Family
ID=55218314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/042904 WO2016019140A1 (en) | 2014-07-30 | 2015-07-30 | Methods, compositions, and kits for analysis of structurally diverse complex lipids |
Country Status (7)
Country | Link |
---|---|
US (1) | US11181535B2 (en,Table 1-8) |
EP (1) | EP3174991B1 (en,Table 1-8) |
JP (1) | JP6810023B2 (en,Table 1-8) |
CN (1) | CN107075539B (en,Table 1-8) |
AU (1) | AU2015296304B2 (en,Table 1-8) |
CA (1) | CA2955204A1 (en,Table 1-8) |
WO (1) | WO2016019140A1 (en,Table 1-8) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183448A1 (en) * | 2017-03-31 | 2018-10-04 | Metabolon, Inc. | Comprehensive and quatitative lipid and tocopherol analysis |
EP3980788A4 (en) * | 2019-06-04 | 2023-12-13 | Avanti Polar Lipids, LLC | UNIVERSAL QUANTITATIVE LIPID STANDARDS FOR USE IN LIPIDOMICS |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7306676B2 (ja) * | 2019-02-26 | 2023-07-11 | 国立大学法人九州大学 | 脂質プロファイリングシステム、脂質プロファイリング方法、及び脂質プロファイリングプログラム |
CN110609097A (zh) * | 2019-09-12 | 2019-12-24 | 谱尼测试集团股份有限公司 | 一种磷脂酰丝氨酸类化合物的筛查方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063118A1 (en) * | 2002-06-26 | 2004-04-01 | Gross Richard W. | Spectrometric quantitation of triglyceride molecular species |
US20070082399A1 (en) * | 2003-07-11 | 2007-04-12 | Tatiana A Egorova-Zachernyuk | Compositions and method for stable isotope labelling of biological compounds |
US20100159540A1 (en) * | 2007-03-26 | 2010-06-24 | Ana Rodriguez | Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof |
WO2014016586A1 (en) * | 2012-07-24 | 2014-01-30 | University Of Dundee | Isotopic labelling of proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4224031A (en) * | 1977-11-15 | 1980-09-23 | Mee John M L | CI Mass spectrometric analysis of physiologically active compounds |
GB0128498D0 (en) * | 2001-11-28 | 2002-01-23 | Inst Of Child Health | International standards for sphingolipids |
WO2003078574A2 (en) | 2002-03-11 | 2003-09-25 | Lipomics Technologies, Inc. | Novel metabolic targets and markers |
CN100567967C (zh) * | 2006-08-31 | 2009-12-09 | 华南理工大学 | 一种定量测定纸浆树脂中甘油三酯含量的方法 |
EP3059592A1 (en) * | 2008-05-28 | 2016-08-24 | Basf Se | Methods for assessing liver toxicity |
US8263413B1 (en) * | 2008-10-17 | 2012-09-11 | Andrew S Hansen | Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry |
SG10201405974SA (en) * | 2009-10-01 | 2014-10-30 | Phenomenome Discoveries Inc | Serum-based biomarkers of pancreatic cancer and uses thereof for diseasedetection and diagnosis |
EP2345897A1 (en) * | 2010-01-18 | 2011-07-20 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | Improved method for the detection of polyunsaturated fatty acids |
CN101824064A (zh) * | 2010-01-29 | 2010-09-08 | 上海化工研究院 | 一种13c标记胆甾醇羧酸酯的合成方法 |
US10705100B1 (en) * | 2013-09-11 | 2020-07-07 | HB Biotech, LLC | Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry |
CN103743851B (zh) * | 2014-02-14 | 2015-06-17 | 中国农业科学院油料作物研究所 | 一种食用油中甘油三酯的单柱二维液相色谱-质谱分析方法及其应用 |
-
2015
- 2015-07-30 EP EP15827995.0A patent/EP3174991B1/en active Active
- 2015-07-30 JP JP2017505546A patent/JP6810023B2/ja active Active
- 2015-07-30 WO PCT/US2015/042904 patent/WO2016019140A1/en active Application Filing
- 2015-07-30 CN CN201580040519.5A patent/CN107075539B/zh active Active
- 2015-07-30 AU AU2015296304A patent/AU2015296304B2/en active Active
- 2015-07-30 CA CA2955204A patent/CA2955204A1/en not_active Abandoned
-
2016
- 2016-08-30 US US15/251,579 patent/US11181535B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040063118A1 (en) * | 2002-06-26 | 2004-04-01 | Gross Richard W. | Spectrometric quantitation of triglyceride molecular species |
US20070082399A1 (en) * | 2003-07-11 | 2007-04-12 | Tatiana A Egorova-Zachernyuk | Compositions and method for stable isotope labelling of biological compounds |
US20100159540A1 (en) * | 2007-03-26 | 2010-06-24 | Ana Rodriguez | Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof |
WO2014016586A1 (en) * | 2012-07-24 | 2014-01-30 | University Of Dundee | Isotopic labelling of proteins |
Non-Patent Citations (34)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183448A1 (en) * | 2017-03-31 | 2018-10-04 | Metabolon, Inc. | Comprehensive and quatitative lipid and tocopherol analysis |
CN110494954A (zh) * | 2017-03-31 | 2019-11-22 | 梅塔博隆股份有限公司 | 脂质和生育酚的综合和定量分析 |
JP2020512559A (ja) * | 2017-03-31 | 2020-04-23 | メタボロン,インコーポレイテッド | 包括的および定量的な脂質およびトコフェロールの分析 |
EP3980788A4 (en) * | 2019-06-04 | 2023-12-13 | Avanti Polar Lipids, LLC | UNIVERSAL QUANTITATIVE LIPID STANDARDS FOR USE IN LIPIDOMICS |
Also Published As
Publication number | Publication date |
---|---|
CN107075539B (zh) | 2021-11-12 |
US11181535B2 (en) | 2021-11-23 |
US20170192023A1 (en) | 2017-07-06 |
EP3174991A1 (en) | 2017-06-07 |
EP3174991B1 (en) | 2024-03-20 |
JP6810023B2 (ja) | 2021-01-06 |
AU2015296304B2 (en) | 2019-08-29 |
AU2015296304A1 (en) | 2017-02-02 |
CA2955204A1 (en) | 2016-02-04 |
CN107075539A (zh) | 2017-08-18 |
JP2017524708A (ja) | 2017-08-31 |
EP3174991A4 (en) | 2018-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wiesner et al. | Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry | |
US20200116743A1 (en) | Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample | |
Miao et al. | Plasma lipidomics reveal profound perturbation of glycerophospholipids, fatty acids, and sphingolipids in diet-induced hyperlipidemia | |
US11181535B2 (en) | Isotopically-labeled cholesteryl ester internal standard composition and kit | |
Özbalci et al. | Quantitative analysis of cellular lipids by nano-electrospray ionization mass spectrometry | |
Postle | Lipidomics | |
CN108445241A (zh) | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 | |
Scherer et al. | Lipid profiling of lipoproteins by electrospray ionization tandem mass spectrometry | |
Guerrera et al. | A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients | |
Huang et al. | Quantitative analysis of 10 classes of phospholipids by ultrahigh-performance liquid chromatography tandem triple-quadrupole mass spectrometry | |
Takeda et al. | Improved quantitation of lipid classes using supercritical fluid chromatography with a charged aerosol detector | |
Afshinnia et al. | Plasma lipidomic profiling identifies a novel complex lipid signature associated with ischemic stroke in chronic kidney disease | |
Zhang et al. | Validation of a multiplexed and targeted lipidomics assay for accurate quantification of lipidomes | |
Song et al. | Characterization of potential plasma biomarkers related to cognitive impairment by untargeted profiling of phospholipids using the HILIC-ESI-IT-TOF-MS system | |
Nakanishi et al. | Qualitative and quantitative analyses of phospholipids by LC–MS for lipidomics | |
Alqarni et al. | A High‐Throughput Method for the Analysis of Erythrocyte Fatty Acids and the Omega‐3 Index | |
Zhang et al. | Development of a targeted hydrophilic interaction liquid chromatography-tandem mass spectrometry based lipidomics platform applied to a coronavirus disease severity study | |
CN105891368A (zh) | 人外周血单个核细胞内乙酰胆碱含量的检测方法 | |
Berry et al. | Analysis of polyunsaturated aminophospholipid molecular species using isotope-tagged derivatives and tandem mass spectrometry/mass spectrometry/mass spectrometry | |
Hori et al. | Rapid quantitative analysis of human serum sphingomyelin species using MALDI-TOF mass spectrometry with lipid hydrolase treatment | |
Mannem | In-Quest of Biomarkers for Alzheimer's Disease and Pharmacokinetic Profile of Anticancer Agents Using LC-MS in Human Plasma | |
Medina et al. | ‘Omic-scale quantitative HILIC-MS/MS approach for circulatory lipid phenotyping in clinical research | |
Zhang et al. | Development of a targeted HILIC-MS/MS based lipidomics platform applied to a coronavirus disease severity study | |
Li | Development of metabolomics and lipidomics workflows for phosphorylated metabolites using ultra-high-performance liquid chromatography with tandem mass spectrometry | |
Pajand Birjandi | Application of Solid Phase Microextraction for Lipid Analysis and Lipidomics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15827995 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2955204 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2017505546 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015296304 Country of ref document: AU Date of ref document: 20150730 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015827995 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015827995 Country of ref document: EP |